Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus

Tadayoshi Hashimoto, Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Yukinori Kurokawa, Masaaki Motoori, Yutaka Kimura, Kiyokazu Nakajima, Eiichi Morii, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

Abstract

Primary malignant melanoma of the esophagus (PMME) has been reported to be a rare and highly malignant disease, and to date a standard treatment strategy has not been established due to limited evidence. The aim of the present study was to investigate the clinicopathological characteristics of this extremely rare disease. A total of 6 out of 2,093 patients with PMME treated in our institution between 1995 and 2016 were retrospectively analyzed and their clinicopathological parameters including treatment course and long-term survival were investigated. The major clinicopathological characteristics of patients were that they were >70 years of age, male sex, dysphagia at first diagnosis, and macroscopic black protruding tumors located in the lower third of the thoracic esophagus. Four of the five patients receiving pretherapeutic endoscopic biopsy were correctly diagnosed with PMME, and two patients received preoperative treatment with ineffective histopathological responses. There were two unresectable cases, one was treated with an immune-checkpoint inhibitor and the other received palliative care. Three of the four patients receiving curative surgery developed hematogenous recurrence within two years of surgery and only one patient with pT1aN0M0 achieved long-term survival. The median overall survival of all six patients was 19.6 (6.4-40.5) months. Patients with stage I disease exhibited significantly more favorable prognoses than those with stage II-IV (P=0.025) and surgically-treated patients had significantly better prognoses than those who did not receive surgery (P=0.018). In conclusion, PMME was associated with highly malignant features and tended to develop hematogenous metastases even after radical resection. Early diagnosis appears to be important to cure this refractory disease.

Original languageEnglish
Pages (from-to)1872-1880
Number of pages9
JournalOncology Letters
Volume18
Issue number2
DOIs
Publication statusPublished - Aug 2019

Fingerprint

Esophagus
Melanoma
Survival
Deglutition Disorders
Rare Diseases
Palliative Care
Early Diagnosis
Thorax
Therapeutics
Neoplasm Metastasis
Biopsy
Recurrence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hashimoto, T., Makino, T., Yamasaki, M., Tanaka, K., Miyazaki, Y., Takahashi, T., ... Doki, Y. (2019). Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus. Oncology Letters, 18(2), 1872-1880. https://doi.org/10.3892/ol.2019.10519

Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus. / Hashimoto, Tadayoshi; Makino, Tomoki; Yamasaki, Makoto; Tanaka, Koji; Miyazaki, Yasuhiro; Takahashi, Tsuyoshi; Kurokawa, Yukinori; Motoori, Masaaki; Kimura, Yutaka; Nakajima, Kiyokazu; Morii, Eiichi; Mori, Masaki; Doki, Yuichiro.

In: Oncology Letters, Vol. 18, No. 2, 08.2019, p. 1872-1880.

Research output: Contribution to journalArticle

Hashimoto, T, Makino, T, Yamasaki, M, Tanaka, K, Miyazaki, Y, Takahashi, T, Kurokawa, Y, Motoori, M, Kimura, Y, Nakajima, K, Morii, E, Mori, M & Doki, Y 2019, 'Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus', Oncology Letters, vol. 18, no. 2, pp. 1872-1880. https://doi.org/10.3892/ol.2019.10519
Hashimoto T, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T et al. Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus. Oncology Letters. 2019 Aug;18(2):1872-1880. https://doi.org/10.3892/ol.2019.10519
Hashimoto, Tadayoshi ; Makino, Tomoki ; Yamasaki, Makoto ; Tanaka, Koji ; Miyazaki, Yasuhiro ; Takahashi, Tsuyoshi ; Kurokawa, Yukinori ; Motoori, Masaaki ; Kimura, Yutaka ; Nakajima, Kiyokazu ; Morii, Eiichi ; Mori, Masaki ; Doki, Yuichiro. / Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus. In: Oncology Letters. 2019 ; Vol. 18, No. 2. pp. 1872-1880.
@article{a9a5e3c176dc4245a777e12ca3404649,
title = "Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus",
abstract = "Primary malignant melanoma of the esophagus (PMME) has been reported to be a rare and highly malignant disease, and to date a standard treatment strategy has not been established due to limited evidence. The aim of the present study was to investigate the clinicopathological characteristics of this extremely rare disease. A total of 6 out of 2,093 patients with PMME treated in our institution between 1995 and 2016 were retrospectively analyzed and their clinicopathological parameters including treatment course and long-term survival were investigated. The major clinicopathological characteristics of patients were that they were >70 years of age, male sex, dysphagia at first diagnosis, and macroscopic black protruding tumors located in the lower third of the thoracic esophagus. Four of the five patients receiving pretherapeutic endoscopic biopsy were correctly diagnosed with PMME, and two patients received preoperative treatment with ineffective histopathological responses. There were two unresectable cases, one was treated with an immune-checkpoint inhibitor and the other received palliative care. Three of the four patients receiving curative surgery developed hematogenous recurrence within two years of surgery and only one patient with pT1aN0M0 achieved long-term survival. The median overall survival of all six patients was 19.6 (6.4-40.5) months. Patients with stage I disease exhibited significantly more favorable prognoses than those with stage II-IV (P=0.025) and surgically-treated patients had significantly better prognoses than those who did not receive surgery (P=0.018). In conclusion, PMME was associated with highly malignant features and tended to develop hematogenous metastases even after radical resection. Early diagnosis appears to be important to cure this refractory disease.",
author = "Tadayoshi Hashimoto and Tomoki Makino and Makoto Yamasaki and Koji Tanaka and Yasuhiro Miyazaki and Tsuyoshi Takahashi and Yukinori Kurokawa and Masaaki Motoori and Yutaka Kimura and Kiyokazu Nakajima and Eiichi Morii and Masaki Mori and Yuichiro Doki",
year = "2019",
month = "8",
doi = "10.3892/ol.2019.10519",
language = "English",
volume = "18",
pages = "1872--1880",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Clinicopathological characteristics and survival of primary malignant melanoma of the esophagus

AU - Hashimoto, Tadayoshi

AU - Makino, Tomoki

AU - Yamasaki, Makoto

AU - Tanaka, Koji

AU - Miyazaki, Yasuhiro

AU - Takahashi, Tsuyoshi

AU - Kurokawa, Yukinori

AU - Motoori, Masaaki

AU - Kimura, Yutaka

AU - Nakajima, Kiyokazu

AU - Morii, Eiichi

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2019/8

Y1 - 2019/8

N2 - Primary malignant melanoma of the esophagus (PMME) has been reported to be a rare and highly malignant disease, and to date a standard treatment strategy has not been established due to limited evidence. The aim of the present study was to investigate the clinicopathological characteristics of this extremely rare disease. A total of 6 out of 2,093 patients with PMME treated in our institution between 1995 and 2016 were retrospectively analyzed and their clinicopathological parameters including treatment course and long-term survival were investigated. The major clinicopathological characteristics of patients were that they were >70 years of age, male sex, dysphagia at first diagnosis, and macroscopic black protruding tumors located in the lower third of the thoracic esophagus. Four of the five patients receiving pretherapeutic endoscopic biopsy were correctly diagnosed with PMME, and two patients received preoperative treatment with ineffective histopathological responses. There were two unresectable cases, one was treated with an immune-checkpoint inhibitor and the other received palliative care. Three of the four patients receiving curative surgery developed hematogenous recurrence within two years of surgery and only one patient with pT1aN0M0 achieved long-term survival. The median overall survival of all six patients was 19.6 (6.4-40.5) months. Patients with stage I disease exhibited significantly more favorable prognoses than those with stage II-IV (P=0.025) and surgically-treated patients had significantly better prognoses than those who did not receive surgery (P=0.018). In conclusion, PMME was associated with highly malignant features and tended to develop hematogenous metastases even after radical resection. Early diagnosis appears to be important to cure this refractory disease.

AB - Primary malignant melanoma of the esophagus (PMME) has been reported to be a rare and highly malignant disease, and to date a standard treatment strategy has not been established due to limited evidence. The aim of the present study was to investigate the clinicopathological characteristics of this extremely rare disease. A total of 6 out of 2,093 patients with PMME treated in our institution between 1995 and 2016 were retrospectively analyzed and their clinicopathological parameters including treatment course and long-term survival were investigated. The major clinicopathological characteristics of patients were that they were >70 years of age, male sex, dysphagia at first diagnosis, and macroscopic black protruding tumors located in the lower third of the thoracic esophagus. Four of the five patients receiving pretherapeutic endoscopic biopsy were correctly diagnosed with PMME, and two patients received preoperative treatment with ineffective histopathological responses. There were two unresectable cases, one was treated with an immune-checkpoint inhibitor and the other received palliative care. Three of the four patients receiving curative surgery developed hematogenous recurrence within two years of surgery and only one patient with pT1aN0M0 achieved long-term survival. The median overall survival of all six patients was 19.6 (6.4-40.5) months. Patients with stage I disease exhibited significantly more favorable prognoses than those with stage II-IV (P=0.025) and surgically-treated patients had significantly better prognoses than those who did not receive surgery (P=0.018). In conclusion, PMME was associated with highly malignant features and tended to develop hematogenous metastases even after radical resection. Early diagnosis appears to be important to cure this refractory disease.

UR - http://www.scopus.com/inward/record.url?scp=85069875420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069875420&partnerID=8YFLogxK

U2 - 10.3892/ol.2019.10519

DO - 10.3892/ol.2019.10519

M3 - Article

AN - SCOPUS:85069875420

VL - 18

SP - 1872

EP - 1880

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -